Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
South, Andrew M;
Tomlinson, Laurie;
Edmonston, Daniel;
Hiremath, Swapnil;
Sparks, Matthew A;
(2020)
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
Nature Reviews Nephrology, 16 (6).
pp. 305-307.
ISSN 1759-5061
DOI: https://doi.org/10.1038/s41581-020-0279-4
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to understand the relationship between the virus and the renin–angiotensin system (RAS) and how this might be affected by RAS inhibitors.